The global preimplantation genetics diagnosis (PGD) market accounted for USD 0.746 billion in 2023 and is expected to reach USD 2.46 billion by 2034 with a CAGR of 11.46% during the forecast period 2024-2034. The market will grow as a result of factors such as the rising incidence of genetic disorders, increasing demand for assisted reproductive technologies (ART), improvements in genetic screening technologies, regulatory support, and ethical considerations, rising R&D investments, and a shift toward personalized medicine.
Growing demand for assisted reproductive technologies (ART) treatments, such as PGD and in vitro fertilization (IVF), is a result of the increasing prevalence of infertility caused by causes such as changing lifestyles, advanced maternal age, and environmental variables. The precision, effectiveness, and dependability of PGD have been increased by technological developments, especially in the areas of next-generation sequencing (NGS), comparative genomic hybridization (CGH), and polymerase chain reaction (PCR). This has led to the widespread use of PGD. For instance, Thermo Fisher Scientific, Inc. introduced two new NGS-based test kits in 2023 to support PGT-A (preimplantation genetic testing for aneuploidy) in IVF and ICSI research.
By product, the reagents and consumables segment accounted for the highest revenue-grossing segment in the global preimplantation genetics diagnosis (PGD) market in 2023 owing to the increasing adoption of advanced genetic screening technologies and the recurrent need for consumables in PGD procedures. For instance, CooperGenomics, a division of The Cooper Companies, developed PGT-Complete in 2022, adding new features to its PGT-A testing. Additionally, the instruments segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for high-throughput and automated systems, advancements in instrument technology, and increasing adoption of preimplantation genetic diagnosis (PGD) procedures worldwide.
By technology, the next-generation sequencing segment accounted for the highest revenue-grossing segment in the global preimplantation genetics diagnosis (PGD) market in 2023 and is predicted to grow at the fastest CAGR during the forecast period owing to the growing demand for comprehensive genetic analysis, technological advancements enhancing sequencing accuracy and efficiency, and increasing applications of next-generation sequencing in preimplantation genetic diagnosis (PGD) procedures. For instance, in July 2022, GenEmbryomics began research using just whole genome sequencing tests to detect genetic disorders in IVF embryos.
By application, the chromosomal abnormalities testing segment accounted for the highest revenue-grossing segment in the global preimplantation genetics diagnosis (PGD) market in 2023 owing to the growing prevalence of chromosomal disorders, increasing awareness about the importance of detecting such abnormalities early in the reproductive process, and advancements in testing technologies enabling more accurate and comprehensive analysis. For instance, Illumina announced in January 2024 that the VeriSeqTM Preimplantation Genetic Testing Solution would be available for testing for monogenic/single gene diseases (PGT-M) and aneuploidy (PGT-A). The objective of this solution is to improve PGD operations' accuracy and efficiency. Additionally, the aneuploidy screening segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for fertility treatments, increasing maternal age, growing awareness about the benefits of aneuploidy screening in reducing the risk of miscarriages and birth defects, and advancements in screening technologies improving accuracy and efficiency.
By end-user, the fertility clinics segment accounted for the highest revenue-grossing segment in the global preimplantation genetics diagnosis (PGD) market in 2023 owing to the increasing demand for assisted reproductive technologies, rising prevalence of infertility, and the central role of fertility clinics in offering comprehensive reproductive services including preimplantation genetic diagnosis (PGD). For instance, Thermo Fisher Scientific announced in November 2023 that it was launching Ion ReproSeqTM PGS Solution, a complete preimplantation genetic screening tool, as part of its PGD product expansion. The goal of this method is to increase IVF operation success rates. Additionally, the research centers and academic labs segment is predicted to grow at the fastest CAGR during the forecast period owing to the expanding research in genetics and reproductive medicine, increasing collaborations between academia and industry, and the pursuit of advancements in preimplantation genetic diagnosis (PGD) technologies and techniques.
North American region is anticipated to have the highest revenue share during the forecast period owing to the advanced healthcare infrastructure, high adoption rates of assisted reproductive technologies (ART), growing prevalence of genetic disorders, and supportive regulatory frameworks facilitating the growth of the preimplantation genetics diagnosis (PGD) market. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness about reproductive health, rising disposable income, expanding healthcare infrastructure, and growing adoption of advanced reproductive technologies including preimplantation genetic diagnosis (PGD) in the region. For instance, CooperSurgical announced in September 2023 that it had acquired Eeva, an AI-powered technology used to enhance embryo selection during IVF procedures. The goal of this transaction is to improve CooperSurgical's standing in the IVF industry.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Growing demand for assisted reproductive technologies (ART) treatments, such as PGD and in vitro fertilization (IVF), is a result of the increasing prevalence of infertility caused by causes such as changing lifestyles, advanced maternal age, and environmental variables. The precision, effectiveness, and dependability of PGD have been increased by technological developments, especially in the areas of next-generation sequencing (NGS), comparative genomic hybridization (CGH), and polymerase chain reaction (PCR). This has led to the widespread use of PGD. For instance, Thermo Fisher Scientific, Inc. introduced two new NGS-based test kits in 2023 to support PGT-A (preimplantation genetic testing for aneuploidy) in IVF and ICSI research.
By product, the reagents and consumables segment accounted for the highest revenue-grossing segment in the global preimplantation genetics diagnosis (PGD) market in 2023 owing to the increasing adoption of advanced genetic screening technologies and the recurrent need for consumables in PGD procedures. For instance, CooperGenomics, a division of The Cooper Companies, developed PGT-Complete in 2022, adding new features to its PGT-A testing. Additionally, the instruments segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for high-throughput and automated systems, advancements in instrument technology, and increasing adoption of preimplantation genetic diagnosis (PGD) procedures worldwide.
By technology, the next-generation sequencing segment accounted for the highest revenue-grossing segment in the global preimplantation genetics diagnosis (PGD) market in 2023 and is predicted to grow at the fastest CAGR during the forecast period owing to the growing demand for comprehensive genetic analysis, technological advancements enhancing sequencing accuracy and efficiency, and increasing applications of next-generation sequencing in preimplantation genetic diagnosis (PGD) procedures. For instance, in July 2022, GenEmbryomics began research using just whole genome sequencing tests to detect genetic disorders in IVF embryos.
By application, the chromosomal abnormalities testing segment accounted for the highest revenue-grossing segment in the global preimplantation genetics diagnosis (PGD) market in 2023 owing to the growing prevalence of chromosomal disorders, increasing awareness about the importance of detecting such abnormalities early in the reproductive process, and advancements in testing technologies enabling more accurate and comprehensive analysis. For instance, Illumina announced in January 2024 that the VeriSeqTM Preimplantation Genetic Testing Solution would be available for testing for monogenic/single gene diseases (PGT-M) and aneuploidy (PGT-A). The objective of this solution is to improve PGD operations' accuracy and efficiency. Additionally, the aneuploidy screening segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for fertility treatments, increasing maternal age, growing awareness about the benefits of aneuploidy screening in reducing the risk of miscarriages and birth defects, and advancements in screening technologies improving accuracy and efficiency.
By end-user, the fertility clinics segment accounted for the highest revenue-grossing segment in the global preimplantation genetics diagnosis (PGD) market in 2023 owing to the increasing demand for assisted reproductive technologies, rising prevalence of infertility, and the central role of fertility clinics in offering comprehensive reproductive services including preimplantation genetic diagnosis (PGD). For instance, Thermo Fisher Scientific announced in November 2023 that it was launching Ion ReproSeqTM PGS Solution, a complete preimplantation genetic screening tool, as part of its PGD product expansion. The goal of this method is to increase IVF operation success rates. Additionally, the research centers and academic labs segment is predicted to grow at the fastest CAGR during the forecast period owing to the expanding research in genetics and reproductive medicine, increasing collaborations between academia and industry, and the pursuit of advancements in preimplantation genetic diagnosis (PGD) technologies and techniques.
North American region is anticipated to have the highest revenue share during the forecast period owing to the advanced healthcare infrastructure, high adoption rates of assisted reproductive technologies (ART), growing prevalence of genetic disorders, and supportive regulatory frameworks facilitating the growth of the preimplantation genetics diagnosis (PGD) market. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness about reproductive health, rising disposable income, expanding healthcare infrastructure, and growing adoption of advanced reproductive technologies including preimplantation genetic diagnosis (PGD) in the region. For instance, CooperSurgical announced in September 2023 that it had acquired Eeva, an AI-powered technology used to enhance embryo selection during IVF procedures. The goal of this transaction is to improve CooperSurgical's standing in the IVF industry.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Product, Technology, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement
Segmentation: Preimplantation Genetics Diagnosis (PGD) Market Report 2023 - 2034
Preimplantation Genetics Diagnosis (PGD) Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Reagents and Consumables
- Instruments
- Software
Preimplantation Genetics Diagnosis (PGD) Market Analysis & Forecast by Technology 2023 - 2034 (Revenue USD Bn)
- Next Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- Fluorescent In-Situ Hybridization (FISH)
- Others
Preimplantation Genetics Diagnosis (PGD) Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Chromosomal Abnormalities
- X-linked Diseases
- Embryo Testing
- Aneuploidy Screening
- HLA Typing
- Other Applications
Preimplantation Genetics Diagnosis (PGD) Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Fertility Centers
- Hospitals
- Diagnostic Centers
- Research Centers and Academic Labs
Preimplantation Genetics Diagnosis (PGD) Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Preimplantation Genetics Diagnosis (PGD) Market: Product Estimates & Trend Analysis
8. Preimplantation Genetics Diagnosis (PGD) Market: Technology Estimates & Trend Analysis
9. Preimplantation Genetics Diagnosis (PGD) Market: Application Estimates & Trend Analysis
10. Preimplantation Genetics Diagnosis (PGD) Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Preimplantation Genetics Diagnosis (PGD) Market
13. Europe Global Preimplantation Genetics Diagnosis (PGD) Market
14. Asia Pacific Global Preimplantation Genetics Diagnosis (PGD) Market
15. Latin America Global Preimplantation Genetics Diagnosis (PGD) Market
16. MEA Global Preimplantation Genetics Diagnosis (PGD) Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Illumina Inc.
- Thermo Fisher Scientific Inc.
- Natera Inc.
- PerkinElmer Inc.
- CooperSurgical Inc.
- Agilent Technologies Inc.
- Oxford Gene Technology (OGT)
- Genesis Genetics
- Reprogenetics
- Vitrolife AB
- IGENOMIX
- Invicta Genetics
- Molecular Biometrics
- CombiMatrix Corporation
- Fertility and Genetics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | October 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 0.75 Billion |
| Forecasted Market Value ( USD | $ 2.46 Billion |
| Compound Annual Growth Rate | 11.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
